$MNKD Mannkind has no collaboration agreements with any Continuous Glucose Monitoring device companies and only one collaboration with a Glucose Monitoring Device company One Drop, which means Mannkind is limiting bringing the benefits of Afrezza to more people. Add to that Mannkind doesn't have a co-promotion agreement with a big pharma company to get more people using Afrezza in the United States and internationally. Mike's commercial strategy since joining Mannkind is terrible and a disservice to diabetes patients and shareholders.
  • 5